文献速递白血病

EUTOS长期生存(ELTS)评分在预测慢性髓性白血病生存方面优于Sokal评分

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
PubMed 文献 · Leukemia · 2020-06-29

在2949例未参与任何评分开发的患者中,ELTS评分在任何比较中均显示更高的风险比和一致性指数,对长期生存的区分度最佳。在5154例分析风险分组差异的患者中,Sokal评分将23%(n=1197)归为高危,其中56%按ELTS评分为非高危且长期生存预后显著更优。ELTS评分在风险组区分上优于Sokal、Euro和EUTOS评分,支持欧洲白血病网推荐优先使用ELTS评分。

要点

  • ELTS评分对长期生存的区分度优于Sokal、Euro和EUTOS评分。
  • Sokal评分将过多患者归为高危,且仅40%归为低危(ELTS评分为60%)。
  • 欧洲白血病网推荐优先使用ELTS评分获显著统计学证据支持。

核心结论

  • ELTS评分在风险组区分和长期生存预测方面优于Sokal、Euro和EUTOS评分。
  • 欧洲白血病网推荐优先使用ELTS评分得到显著统计学证据支持。

研究设计与样本

  • 在2949例未参与任何评分开发的患者中比较各评分的预后性能。
  • 在5154例患者中分析风险分组分类差异。

主要发现

  • 在2949例患者中,ELTS评分在任何比较中均显示更高的风险比和一致性指数,对长期生存的区分度最佳。
  • 在5154例患者中,Sokal评分将23%(n=1197)归为高危。
  • 在1197例Sokal高危患者中,56%按ELTS评分为非高危,其长期生存预后显著优于两种评分均为高危的526例患者。
  • Sokal评分将相对较少的患者(40%)归为低危,而ELTS评分为60%。

关键数值与推荐

  • Sokal评分高危组1197例(占5154例的23%),其中56%按ELTS评分为非高危。
  • 两种评分均为高危的患者526例。
  • Sokal评分低危占40%,ELTS评分低危占60%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any score development, higher hazard ratios and concordance indices in any comparison demonstrated the best discrimination of long-term survival with the ELTS score. In a second step, of 5154 patients analyzed to investigate risk group classification differences, 23% (n = 1197) were allocated to high-risk by the Sokal score. Of the 1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable long-term survival prognosis than the 526 high-risk patients according to both scores. The Sokal score identified too many patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score). Inappropriate risk classification jeopardizes optimal treatment selection. The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination. The recent recommendation of the European LeukemiaNet for preferred use of the ELTS score was supported with significant statistical evidence.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020. PMID: 32601376. doi:10.1038/s41375-020-0931-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。